arrow
P

Paolo Corradini

university of milan
H指数:88
被引数:2.8万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Real-world CAR-T practice patterns in patients with mantle cell lymphoma: an international survey on behalf of the EBMT lymphoma working party

套细胞淋巴瘤患者中真实世界CAR-T实践模式:EBMT淋巴瘤工作组发起的一项国际调查

2026-08-180
PRE
Molecular biomarkers as key determinants of outcome in mantle cell lymphoma: results from the FIL V-RBAC trial

分子生物标志物作为套细胞淋巴瘤预后的关键决定因素:FIL V-RBAC试验结果

2026-07-280
OA
T-cell dynamics, CD8/NK ratio and tumor survival hallmarks determine response to T-cell bispecific forimtamig in myeloma

T细胞动力学、CD8/NK比率及肿瘤生存特征决定T细胞双特异性抗体formitamig对骨髓瘤的反应

2026-01-010
OA
CAR T expansion and systemic inflammation: diverging impacts on large B-cell lymphoma therapy in the multicenter CART SIE study
2025-11-011
OA
Trends in GVHD Epidemiology, Prophylaxis and Management: The Gruppo Italiano per il Trapianto di Midollo Osseo, Cellule Staminali Emopoietiche e Terapia Cellulare (GITMO) GVHD24 Study

移植物抗宿主病流行病学、预防和管理趋势:意大利骨髓移植、造血干细胞和细胞治疗小组(GITMO)GVHD24研究

2025-11-010
PRE
Advanced stage classical Hodgkin lymphoma patients with a positive interim-PET (PET-2) Deauville score 5 after 2 ABVD cycles: a pooled analysis of three multicenter trials

III期经典霍奇金淋巴瘤患者在接受2个ABVD疗程后,中期PET(PET-2)德瓦伊评分5分的患者:三项多中心试验的合并分析

2025-10-160
OA
Treatment persistence and overall survival in myelofibrosis treated with ruxolitinib were not affected by the covid-19 pandemic, despite the reduced starting dose: Analysis of AIFA registries

尽管起始剂量有所减少,接受鲁索利替尼治疗的骨髓纤维化患者的治疗持续性和总生存期并未受到COVID-19大流行的影响:意大利药品管理局登记数据分析

2025-09-200
OA
Rituximab, bendamustine, and cytarabine followed by venetoclax in older patients with high-risk mantle cell lymphoma (FIL_V-RBAC): a multicentre, single-arm, phase 2 study

利妥昔单抗、 bendamustine 和 cytarabine,随后使用 venetoclax 治疗高风险套细胞淋巴瘤老年患者(FIL_V-RBAC):一项多中心、单臂、Ⅱ期研究

2025-09-170
PRE
Comparative Effectiveness of Ciltacabtagene Autoleucel in CARTITUDE-4 Versus Real-World Physician’s Choice of Therapy from the Flatiron Registry in Lenalidomide-Refractory Multiple Myeloma

Ciltacabtagene autoleucel在CARTITUDE-4研究中的比较有效性,与来自Flatiron登记研究中来那度胺难治性多发性骨髓瘤的真实世界医生选择疗法进行比较

2025-08-060
OAAI
Allogeneic transplantation after failure of chimeric antigen receptor-T cells and exposure to bispecific antibodies: Feasibility, safety and survival outcomes

同种异体移植在嵌合抗原受体-T细胞失败并接触双特异性抗体后的可行性、安全性和生存结局

2025-07-220
OAAI
Outcomes of Allogeneic HCT in Hodgkin Lymphoma in the Era of Checkpoint Inhibitors: A Joint CIBMTR and EBMT Analysis.

异基因造血干细胞移植在免疫检查点抑制剂时代霍奇金淋巴瘤中的疗效:CIBMTR与EBMT联合分析。

Blood
IF23.1
2025-07-090
PRE
Long-Term Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma: An Italian Multicenter Collaborative Study

异基因造血干细胞移植治疗复发/难治性B细胞非霍奇金淋巴瘤的长期预后:一项意大利多中心合作研究

2025-06-010
PREAI
Total Metabolic Tumor Volume Is a Strong Independent Prognostic Factor in Follicular Lymphomas: Results From a Sub-Study of the FOLL12 Trial

总代谢肿瘤体积是滤泡性淋巴瘤的一个强独立预后因素:FOLL12试验子研究的结果

2025-05-140
OA
Comparative Efficacy of Ciltacabtagene Autoleucel Versus Standard-of-Care Treatments for Patients with Previously Treated Relapsed or Refractory Multiple Myeloma: A Matching-Adjusted Indirect Comparison

比较cilta-cabtagene autoleucel与标准护理治疗用于既往接受过治疗的复发或难治性多发性骨髓瘤患者的疗效:一项匹配调整间接比较研究

2025-05-120
OA
Prognostic role of interim PET in follicular lymphoma: a post hoc study of FOLL12 trial by Fondazione Italiana Linfomi
2025-01-010
OA
Prospective Validation of CAR-HEMATOTOX and a Simplified Version Predict Survival in Patients with Large B-Cell Lymphoma Treated with Anti-CD19 CAR T-Cells: Data from CART-SIE Study

CAR-hematox的前瞻性验证和简化版本预测Anti-CD19 CAR T细胞治疗的大b细胞淋巴瘤患者的生存: 来自cart-sie研究的数据

2025-01-010
OAAI